A Phase 1 Randomized, Single-Blind, Three-Arm, Staggered Parallel Study to Assess the Safety, Tolerability, and Pharmacokinetics of Atorvo+™ in Healthy Adult Participants
Latest Information Update: 07 Oct 2024
Price :
$35 *
At a glance
- Drugs Atorvastatin/cannabidiol (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- 07 Oct 2024 New trial record